跳至主要内容
临床试验/NCT00431275
NCT00431275已完成1 期

An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations

AstraZeneca1 个研究点 分布在 1 个国家目标入组 85 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
85
试验地点
1
主要终点
Pharmacokinetics: maximum plasma concentration of CP-675,206

研究概览

简要总结

This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Stage III or Stage IV melanoma
  • •No evidence of disease following resection of melanoma lesions
  • •Recovered from all prior surgical or adjuvant treatment-related toxicities

排除标准

  • •History of chronic inflammatory or autoimmune disease
  • •History of inflammatory bowel disease

研究组 & 干预措施

Current Formulation

Experimental

Current Formulation

干预措施: CP-675,206 (Drug)

Commercial Formulation

Experimental

Commercial Formulation

干预措施: CP-675,206 (Drug)

结局指标

主要结局

Pharmacokinetics: maximum plasma concentration of CP-675,206

时间窗: 1 hour

Pharmacokinetics: AUC, defined as the area under the concentration -time curve

时间窗: Time 0 to Day 85

次要结局

  • Human-anti-human antibodies(1 year)
  • Adverse events(1 year)
  • Safety laboratory tests(1 year)
  • Proportion of patients alive and free of disease at 1 year(1 year)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验